{
  "docId": "019de072-afcf-751b-be79-65bbe03fb0c7",
  "docSlug": "a4681640730b4446aa1f6ee077b8a572",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 23 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 23,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "The slide presents key clinical trial results for a drug candidate, focusing on response rates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/8",
  "deckHref": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7",
  "deckJsonHref": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json",
  "deckAnchorHref": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "* 3 PRs have been confirmed by RECIST 1.1, 1 PR is unconfirmed",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1de67c97-af54-4085-8218-8dc23865617d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "list",
      "text": "Clinical Benefit Rate at the Efficacious Dose (10-12.5 mg/kg): Monotherapy: 68.8% (11/16), Combination: 76.5% (13/17)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d41b0696-f874-43d3-aebc-dc6dc62f8347",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Overall Response Rate at the Efficacious Dose (10-12.5 mg/kg): Monotherapy: 18.8% ORR (3/16), Combination: 23.5% ORR (4/17)*",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4679c7f-fef4-4e59-b49a-488c1b807cae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "title",
      "text": "CTX-009 - Phase 1 Studies Clinical Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d68ca45-e7e6-4026-bc50-9d0dec6812e3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 8,
      "beatId": "c48aac4e-cbcc-46b6-a057-f734bc543a6f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The traction section presents clinical data for CTX-009",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 23,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667",
      "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company",
      "position": 0,
      "objective": "Highlight the potential consequences of not investing in Compass Therapeutics",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}